WASHINGTON — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

Colombian billionaire Jaime Gilinski Bacal is open to selling his majority stake in British lender Metro Bank and has ...

A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

The drug, lamivudine, appears to improve vision that’s being threatened by diabetic macular edema (DME), an eye condition in ...

A twice-yearly injectable drug for the prevention of HIV infection has been approved by the United States’ Food and Drug ...

Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.